Company Overview

Immatics N.V. is a clinical-stage biotechnology company focused on developing T cell–based immunotherapies for the treatment of cancer. The company operates within the biotechnology and oncology immunotherapy industries, with a strategic emphasis on harnessing the immune system to target solid tumors. Its core approach centers on identifying tumor-specific peptides presented by human leukocyte antigens (HLAs) and designing therapies that direct T cells precisely to cancer cells.

The company’s primary business lines include T cell receptor–engineered T cell therapies and T cell–engaging bispecific biologics, which together represent its main revenue drivers through research collaborations, upfront payments, milestones, and potential future product commercialization. Immatics primarily serves oncology patients through partnerships with large pharmaceutical companies and internal clinical development programs. Founded in 2000 in Germany as Immatics Biotechnologies GmbH, the company evolved from a discovery-focused enterprise into a clinically oriented, publicly traded company following its listing on the Nasdaq in 2020.

Business Operations

Immatics conducts its operations through integrated discovery, development, and clinical activities organized around two main technology platforms: ACTengine® for adoptive cell therapies and TCER® for T cell–engaging receptor bispecifics. These platforms enable the company to generate a pipeline of proprietary product candidates targeting multiple solid tumor indications. Revenue is currently generated primarily through strategic collaborations, research funding, and milestone payments rather than commercial product sales.

Operations span both domestic and international locations, with core research and development activities in Europe and the United States. The company controls proprietary antigen discovery technologies and maintains internal manufacturing and translational research capabilities. Immatics has established major partnerships with Amgen, Bristol Myers Squibb, and GlaxoSmithKline, and operates through subsidiaries including Immatics Biotechnologies GmbH and Immatics US, Inc., which support regional R&D and clinical operations.

Strategic Position & Investments

Immatics’ strategic direction is focused on advancing a diversified clinical pipeline while leveraging partnerships to share development risk and expand global reach. Growth initiatives emphasize progressing wholly owned clinical programs into later-stage trials and expanding the application of its antigen discovery platform to additional tumor types. The company has invested significantly in building scalable T cell therapy technologies and strengthening its translational science capabilities.

Rather than operating as a holding company, Immatics maintains a portfolio of internal programs complemented by partnered assets developed jointly with pharmaceutical collaborators. It is actively involved in emerging areas of cellular immunotherapy, including next-generation engineered T cell receptors and bispecific immune engagers, positioning the company at the intersection of precision oncology and immune engineering.

Geographic Footprint

Immatics is headquartered in Tübingen, Germany, with a significant operational presence in Houston, Texas, reflecting its dual European–U.S. footprint. The company’s activities span Europe and North America, encompassing research, clinical development, and corporate functions. Clinical trials are conducted across multiple international sites, supporting a broad patient recruitment base.

Through its strategic partnerships with multinational pharmaceutical companies, Immatics’ technologies and programs have an indirect presence in additional global markets, including Asia-Pacific regions, where collaborators may pursue development and commercialization activities. This structure allows the company to maintain global influence without extensive standalone commercial infrastructure.

Leadership & Governance

Immatics is led by a management team with deep experience in immunology, oncology drug development, and biotechnology commercialization. The leadership philosophy emphasizes scientific rigor, data-driven clinical development, and partnership-based growth to maximize the therapeutic and commercial potential of its platforms.

Key executives include:

• Harpreet Singh – Chief Executive Officer and Co-Founder
• Paul Higham – Chief Financial Officer
• Christian M. Hedrich – Chief Medical Officer
• Jens Reimann – Chief Operating Officer
• Patrick Gruber – Chief Scientific Officer